Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VRDN
stocks logo

VRDN

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
47.00K
-34.72%
-0.978
-4.1%
47.00K
-45.35%
-0.975
-15.26%
47.00K
-34.72%
-1.013
+25.03%
Estimates Revision
The market is revising Upward the revenue expectations for Viridian Therapeutics, Inc. (VRDN) for FY2025, with the revenue forecasts being adjusted by 19.75% over the past three months. During the same period, the stock price has changed by 28.12%.
Revenue Estimates for FY2025
Revise Upward
up Image
+19.75%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.17%
In Past 3 Month
Stock Price
Go Up
up Image
+28.12%
In Past 3 Month
12 Analyst Rating
up Image0
Wall Street analysts forecast VRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRDN is 38.80 USD with a low forecast of 19.00 USD and a high forecast of 61.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
2 Hold
0 Sell
Strong Buy
up Image0
Current: 17.040
sliders
Low
19.00
Averages
38.80
High
61.00
up Image0
Current: 17.040
sliders
Low
19.00
Averages
38.80
High
61.00
Evercore ISI
Outperform
downgrade
$41 -> $38
2025-07-11
New
Reason
Evercore ISI
Price Target
$41 -> $38
2025-07-11
New
downgrade
Outperform
Reason
Evercore ISI lowered the firm's price target on Viridian Therapeutics to $38 from $41 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$34
2025-04-23
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$34
2025-04-23
Reiterates
Strong Buy
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$38
2025-01-07
Reason
Needham
Serge Belanger
Price Target
$38
2025-01-07
Reiterates
Strong Buy
Reason
Wells Fargo
Derek Archila
Buy
to
Hold
Downgrades
$27
2024-12-19
Reason
Wells Fargo
Derek Archila
Price Target
$27
2024-12-19
Downgrades
Buy
to
Hold
Reason
Wells Fargo downgraded Viridian Therapeutics to Equal Weight from Overweight with a price target of $27, down from $37. The firm says its thesis on veligrotug played out in thyroid eye disease, and that the drug will get approved and be successful commercially. That said, the approval won't be until the second half of 2026 along with VRDN-003's Phase 3 data, Viridian's key value driver, the analyst tells investors in a research note. It cites a lack of catalysts for the downgrade.
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$34
2024-12-17
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$34
2024-12-17
Reiterates
Strong Buy
Reason
RBC Capital
Gregory Renza
Buy
Maintains
$44 → $47
2024-12-17
Reason
RBC Capital
Gregory Renza
Price Target
$44 → $47
2024-12-17
Maintains
Buy
Reason
RBC Capital analyst Gregory Renza raised the firm's price target on Viridian Therapeutics (VRDN) to $47 from $44 and keeps an Outperform rating on the shares. The company's positive THRIVE-2 topline for veligrotug - Veli - in chronic TED comes as a second big win for the program and could be the game changer on differentiation that Viridian bulls have been waiting for, the analyst tells investors in a research note. Importantly, Veli's 56% diplopia response and complete resolution in 32% of patients marks the first pivotal to demonstrate statistically significant diplopia improvement and serves as a key differentiator to Amgen's (AMGN) Tepezza, the firm added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Viridian Therapeutics Inc (VRDN.O) is -4.14, compared to its 5-year average forward P/E of -4.50. For a more detailed relative valuation and DCF analysis to assess Viridian Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.50
Current PE
-4.14
Overvalued PE
-3.15
Undervalued PE
-5.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.27
Current EV/EBITDA
-3.04
Overvalued EV/EBITDA
-1.18
Undervalued EV/EBITDA
-5.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2472.74
Current PS
7976.64
Overvalued PS
5035.65
Undervalued PS
-90.18

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

VRDN News & Events

Events Timeline

(ET)
2025-05-20
07:05:26
Viridian Therapeutics announces long-term durability data from THRIVE trial
select
2025-05-07 (ET)
2025-05-07
16:18:12
Viridian Therapeutics receives FDA breakthrough designation for Veligrotug
select
2025-04-07 (ET)
2025-04-07
07:02:55
Viridian Therapeutics appoints Ajer to its board of directors
select
Sign Up For More Events
Sign Up For More Events

News

Preview
5.0
06-06NASDAQ.COM
Viridian Issues Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Stock Options Granted: Viridian Therapeutics has granted non-qualified stock options for 23,400 shares to a new employee, effective June 2, 2025, approved by the Board's Compensation Committee and compliant with Nasdaq rules.

  • Vesting Schedule and Stock Performance: The options will vest over four years, with 25% after one year and the rest monthly; as of Thursday, VRDN's stock closed at $14.24, showing a slight increase.

Preview
9.0
06-05Newsfilter
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Stock Options Grant: Viridian Therapeutics announced the approval of non-qualified stock options for 23,400 shares to a new employee as an inducement for employment, with vesting over four years and an exercise price equal to the stock's closing price on the grant date.

  • Clinical Advancements: The company is advancing multiple candidates for thyroid eye disease (TED), including VRDN-001 and VRDN-003, which are undergoing global phase 3 clinical trials, alongside developing neonatal Fc receptor inhibitors for autoimmune diseases.

Preview
1.0
05-30Newsfilter
Viridian Therapeutics to Participate in Upcoming June Investor Conferences

  • Upcoming Investor Conferences: Viridian Therapeutics will present at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Annual Global Healthcare Conference on June 9, with live webcasts available on their website.

  • Clinical Advancements: The company is advancing multiple candidates for thyroid eye disease (TED), including VRDN-001 and VRDN-003, both of which have shown positive results in phase 3 clinical trials, as well as developing FcRn inhibitors for autoimmune diseases.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Viridian Therapeutics Inc (VRDN) stock price today?

The current price of VRDN is 17.04 USD — it has decreased -0.53 % in the last trading day.

arrow icon

What is Viridian Therapeutics Inc (VRDN)'s business?

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

arrow icon

What is the price predicton of VRDN Stock?

Wall Street analysts forecast VRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRDN is 38.80 USD with a low forecast of 19.00 USD and a high forecast of 61.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Viridian Therapeutics Inc (VRDN)'s revenue for the last quarter?

Viridian Therapeutics Inc revenue for the last quarter amounts to 72.00K USD, decreased 0.00 % YoY.

arrow icon

What is Viridian Therapeutics Inc (VRDN)'s earnings per share (EPS) for the last quarter?

Viridian Therapeutics Inc. EPS for the last quarter amounts to -1.07 USD, increased 35.44 % YoY.

arrow icon

What changes have occurred in the market's expectations for Viridian Therapeutics Inc (VRDN)'s fundamentals?

The market is revising Upward the revenue expectations for Viridian Therapeutics, Inc. (VRDN) for FY2025, with the revenue forecasts being adjusted by 19.75% over the past three months. During the same period, the stock price has changed by 28.12%.
arrow icon

How many employees does Viridian Therapeutics Inc (VRDN). have?

Viridian Therapeutics Inc (VRDN) has 143 emplpoyees as of July 13 2025.

arrow icon

What is Viridian Therapeutics Inc (VRDN) market cap?

Today VRDN has the market capitalization of 1.40B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free